

**EXPRESSION AND PURIFICATION OF
RECOMBINANT LipL32 PROTEIN AND
EVALUATION OF ITS USE IN ELISA FOR THE
DIAGNOSIS OF LEPTOSPIROSIS**



YUSZNIAHYATI BINTI YAAKOB

UMMS
UNIVERSITI MALAYSIA SABAH

**BIOTECHNOLOGY RESEARCH INSTITUTE
UNIVERSITI MALAYSIA SABAH
2016**

**EXPRESSION AND PURIFICATION OF
RECOMBINANT LipL32 PROTEIN AND
EVALUATION OF ITS USE IN ELISA FOR THE
DIAGNOSIS OF LEPTOSPIROSIS**

YUSZNIAHYATI BINTI YAAKOB

**THIS IS SUBMITTED IN PARTIAL FULFILLMENT
FOR THE DEGREE OF MASTER OF SCIENCE**

The image contains a large, light grey watermark of the Universiti Malaysia Sabah logo and text. The logo is circular with a shield in the center, and the text 'UNIVERSITI MALAYSIA SABAH' is written around the perimeter. To the right of the logo, the letters 'UMS' are written in a large, bold, sans-serif font, with 'UNIVERSITI MALAYSIA SABAH' written in a smaller font below it.

**BIOTECHNOLOGY RESEARCH INSTITUTE
UNIVERSITI MALAYSIA SABAH
2016**

DECLARATION

I hereby declare that the material in this thesis is my own except for quotations, excerpts, equations, summaries and references, which have been duly acknowledged.

19 July 2016

Yuszniahayati Binti Yaakob

MZ1321011T



UMS
UNIVERSITI MALAYSIA SABAH

CERTIFICATION

NAME : **YUSZNIAHYATI BINTI YAAKOB**
MATRIC NO : **MZ1321011T**
TITLE : **EXPRESSION AND PURIFICATION OF RECOMBINANT
LipL32 PROTEIN AND EVALUATION OF ITS USE IN
ELISA FOR THE DIAGNOSIS OF LEPTOSPIROSIS**
DEGREE : **MASTER OF SCIENCE (BIOTECHNOLOGY)**

CERTIFIED BY;

1. SUPERVISOR (CHAIRPERSON)

Associate Professor Dr. Daisy Vanitha John

Signature



UMS
UNIVERSITI MALAYSIA SABAH

2. COMMITTEE MEMBER 1

Assoc Prof. Dr. Kenneth Francis Rodrigues

3. COMMITTEE MEMBER 2

Mdm. Sophia Lau Tiek Ying

ACKNOWLEDGEMENT

Firstly, I am grateful to Allah S.W.T because with HIS consent, this research for my Master of Science (Biotechnology) programme has been fully accomplished within the prescribed time. This work was supervised by Associate Professor Dr. Daisy Vanitha John, Dr. Kenneth Francis Rodrigues and Mdm Sophia Lau Tiek Ying. I would like to thank them for their great help during my work, ever-lasting optimism and ability to always see the possibilities in every situation. Especially to Assoc. Prof. Dr. Daisy and Dr. Kenneth, thank you for the suggestions and encouragement throughout my thesis writing. I would also like to thank all my other colleagues whom I have benefited greatly from, both professionally and socially, especially Fernandes Opook, Rolando Robert, Noraini, Lia Natasha, Iskandar and lab assistants (Emran and Azian). A big appreciation to UMS, for funding this research. Without the funding, this project wouldn't go smoothly as planned. Special thanks to Pn Rashidah from Kota Kinabalu Public Health Laboratory and Tuaran Hospital for providing me serum samples for this project. Most importantly, I would like to give the highest appreciation to my mother, Puan Hajah Undrah Binti Saidin and to the rest of my beloved family, for the moral and financial supports, advices and prayers that you have always given to me. Lastly, I would like to thank all parties that were involved either directly or indirectly in the execution of this research project. The efforts put in by everyone involved have always motivated me and made me optimistic in facing any obstacles that I have been through while I was doing this project. I am hoping all the efforts and hard works will be blessed by Allah S.W.T.

Yuszniahhyati Binti Yaakob

19 July 2016

ABSTRACT

Leptospirosis is a zoonotic disease caused by the spirochete, *Leptospira interrogans* (*L. interrogans*). Microscopic Agglutination Test (MAT) is a reference method for the diagnosis of Leptospirosis. However, this method is time consuming and laborious. ELISA using recombinant antigens has proven to be a good diagnostic test for Leptospirosis. *Leptospira* outer membrane protein (OMP), LipL32 is conserved in pathogenic species, and play an important role in immunopathogenicity and serodiagnosis. The objectives of this study were, to express and purify the synthetic *lip32* gene, to determine the presence of *Leptospira*-specific antibodies in human serum samples using synthetic rLipL32 antigen in ELISA and to measure the level of regulatory cytokine, IL-10 for the determination of disease severity. In this study, *lip32* gene was synthetically designed and expressed in *Escherichia coli* (*E. coli*) expression vector BL21 (DE3) and the protein was purified by immobilized metal affinity chromatography (IMAC). The purified rLipL32 was used as an antigen to detect *Leptospira*-specific IgM and IgG by ELISA. A total of 53 human serum samples (20 MAT positive samples, 20 MAT negative samples, 11 unknown serum samples and 2 RCPA serum samples) were tested. ELISA results showed that all MAT positive serum samples were positive for IgG and only 65 % (n=13) of these samples were positive for IgM. For the MAT negative serum samples, 25 % (n=5) and 45 % (n=9) of the samples were positive for IgM and IgG respectively by ELISA. The synthetic rLipL32 based ELISA scored 71 % in the RCPA programme out of the total participants in the survey. The MAT positive serum samples were tested for the presence of the regulatory cytokine, IL-10 to determine the disease severity. The concentration of IL-10 in all human serum samples ranged from 10.8 ± 0.04 pg/mL to 31.9 ± 1.38 pg/mL. When compared to the previous study, this level of IL-10 concentrations shows the mild and non-fatal outcome of Leptospirosis disease. These results demonstrates that ELISA based on synthetic rLipL32 antigen was able to detect *Leptospira*-specific IgM (sensitivity 65 % and specificity 75 %) and IgG (sensitivity 100 % and specificity 55 %) in the human serum samples. Synthetic rLipL32 based ELISA is able to detect *Leptospira*-specific antibodies in human serum samples and has the potential to serve as a rapid diagnostic test for Leptospirosis and for determination of seroprevalence in the community.

ABSTRAK

EXPRESI DAN PENULENAN PROTEIN REKOMBINAN LipL32 DAN PENGGUNAANNYA DALAM ELISA BAGI DIAGNOSIS PENYAKIT LEPTOSPIROSIS

Leptospirosis adalah penyakit zoonosis yang disebabkan oleh sejenis spirochete, *Leptospira interrogans* (*L. interrogans*). Ujian Pengumpulan Mikroskopik (MAT) adalah satu kaedah rujukan bagi diagnosis penyakit *Leptospirosis*. Walau bagaimanapun, kaedah ini memakan masa dan agak sukar. ELISA menggunakan protein rekombinan sebagai antigen telah terbukti sebagai ujian diagnostik yang baik untuk *Leptospirosis*. Protein membran luar (OMP) *Leptospira*, LipL32 dipulihara dalam spesies patogenik, dan memainkan peranan penting dalam 'immunopathogenicity' dan serodiagnosis. Objektif bagi kajian ini adalah mengekspres dan menuliskan gen sintetik *lipl32*, menentukan kehadiran antibodi *Leptospira*-khusus dalam sampel serum manusia menggunakan sintetik protein rLipL32 sebagai antigen dalam ELISA dan mengukur tahap cytokine kawal selia, IL-10 bagi menentukan keterukan penyakit *Leptospirosis*. Dalam kajian ini, gen *lipl32* direka secara sintetik dan diekpres dalam *Escherichia coli* (*E. coli*) BL21 vektor (DE3) dan protein dituliskan menggunakan 'immobilized metal affinity chromatography' (IMAC). Protein rLipL32 yang dituliskan, telah digunakan sebagai antigen untuk mengesan antibodi *Leptospira*-khusus oleh ELISA. Sebanyak 53 sampel serum manusia (20 MAT sampel positif, 20 MAT negatif sampel, 11 serum sampel yang tidak diketahui dan 2 serum sampel dari RCPA) telah diuji. Keputusan ELISA menunjukkan bahawa semua sampel serum positif MAT adalah positif untuk IgG dan hanya 65 % ($n = 13$) sampel ini adalah positif bagi IgM. Bagi sampel serum negatif MAT, 25 % ($n = 5$) dan 45 % ($n = 9$) sampel adalah positif untuk IgM dan IgG masing-masing dalam ELISA. Bagi program RCPA, ELISA berdasarkan protein rLipL32 sintetik menunjukkan keputusan sebanyak 71 % daripada jumlah peserta yang menyertai program tersebut. Sampel serum positif MAT telah diuji bagi kehadiran cytokine kawal-selia, IL-10 bagi menentukan keterukan penyakit *Leptospirosis*. Kepekatan IL-10 dalam semua sampel serum manusia adalah di antara 10.8 ± 0.04 pg/mL kepada 31.9 ± 1.38 pg/mL. Berdasarkan perbandingan dengan kajian sebelumnya, tahap kepekatan IL-10 dalam kajian ini menunjukkan penyakit *Leptospirosis* yang tidak membawa kepada maut. Keputusan menunjukkan bahawa ELISA berdasarkan antigen rLipL32 sintetik dapat mengesan *Leptospira*-khusus IgM (sensitiviti 65 % dan spesifisiti 75 %) dan IgG (sensitiviti 100 % dan spesifisiti 55 %) dalam sampel serum manusia. ELISA berdasarkan rLipL32 mampu mengesan antibodi *Leptospira*-khusus dalam sampel serum manusia dan mempunyai potensi sebagai ujian diagnostik pantas bagi *Leptospirosis* dan menentukan 'seroprevalence' dalam kalangan masyarakat.


TABLE OF CONTENTS

	Page
TITLE	
DECLARATION	ii
CERTIFICATION	iii
ACKNOWLEDGEMENT	iv
ABSTRACT	v
<i>ABSTRAK</i>	vi
TABLE OF CONTENTS	vii
LIST OF TABLES	xi
LIST OF FIGURES	xii
LIST OF ABBREVIATIONS	xv
LIST OF SYMBOLS	xvi
LIST OF APPENDICES	xvii
CHAPTER 1: INTRODUCTION	1
1.1 Preface	1
1.2 Objectives	3
1.3 Research Approach	4
CHAPTER 2: LITERATURE REVIEW	5
2.1 Overview of Leptospirosis	5
2.2 <i>Leptospira</i> , The Organism	6
2.3 History of Leptospirosis	9
2.4 Global Epidemiology of Leptospirosis	10
2.5 Leptospirosis in Malaysia	11
2.6 Mode of Transmissions	13
2.7 Treatments and Preventive Measures	13
2.8 Mechanism of Pathogenesis	15
2.8.1 <i>Leptospira</i> OMP, LipL32	16

2.9	Immunoglobulin	18
2.9.1	Immunoglobulin-G (IgG)	19
2.9.2	Immunoglobulin-M (IgM)	20
2.10	Weil's Disease	22
2.10.1	Role of Cytokines in Weil's Disease	22
a.	Tumour Necrosis Factor alpha(TNF- α)	23
b.	Interleukin-10 (IL-10)	23
c.	Interleukin-8 (IL-8)	24
d.	Interleukin-6 (IL-6)	24
e.	Interleukin-1 β (IL-1 β)	25
2.11	Diagnostic Methods	25
2.11.1	Dark Field Microscopy (DFM)	26
2.11.2	Rapid Nucleic Acid Diagnostic Test	26
2.11.3	Rapid Antibody-Based Diagnostic Test	27
a.	Microscopic Agglutination Test (MAT)	27
b.	Enzyme-Linked Immunosorbent Assay	27
2.11.4	Other serological tests	28
2.12	Codon Optimization in Protein Expression	31
CHAPTER 3: MATERIALS AND METHODS		33
3.1	Generation of Synthetic <i>lip32</i> Gene	33
3.2	Reconstitution of Codon Optimized <i>lip32</i> Gene	33
3.3	Transformation of <i>lip32</i> Gene in <i>E. coli</i> BL21 (DE3)	33
3.4	Screening of Transformation for <i>lip32</i> Inserts	34
3.4.1	Analysis of The Transformation by Colony PCR Amplification	34
3.4.2	Alkaline Lysis Miniprep	36
3.4.3	Analysis of Positive Transformants by Restriction Enzyme Digestion	37
3.5	Expression Study of Recombinant LipL32 (rLipL32) Protein	37
3.5.1	Overexpression of rLipL32 in <i>E. coli</i> BL21 (DE3)	38
3.5.2	Cell Disruption, Washing and Isolation of rLipL32 Protein for Time Course Expression Study	38
3.5.3	Preparation of Sodium Dodecyl Sulphate for Gel Electrophoresis (SDS-PAGE)	39
3.5.4	Sample Preparations for SDS-PAGE	40
3.6	Production of rLipL32 Protein	40
3.6.1	Cell Disruption, Washing Solubilization and Isolation of Inclusion Bodies	41

3.7	Purification of rLipL32 Protein	42
3.8	Quantification of Purified rLipL32 Protein using Bradford Assay	44
3.9	Detection of Leptospira-Specific IgM and IgG in ELISA	44
3.9.1	Serum Samples for ELISA	44
3.9.2	ELISA Protocol	45
3.10	Sensitivity and Specificity of rLipL32 ELISA Assay	45
3.11	Measuring The Level of Regulatory Cytokine, Interleukin-10 (IL-10) for Determination of Disease Severity	46
CHAPTER 4: RESULTS		48
4.1	Generation of Synthetic <i>lip32</i> Gene	48
4.2	Screening of Transformant for <i>lip32</i> Inserts	49
4.2.1	Analysis of Positive Transformants by Colony PCR Amplification	50
4.2.2	Analysis of Positive Transformants by Restriction Enzyme Digestion	51
4.3	Expression Study of rLipL32 Protein	52
4.3.1	Expression Level of <i>lip32</i> Gene in <i>E.coli</i> and Solubility of the rLipL32 Protein	52
4.4	Purification of rLipL32 Protein	55
4.4.1	SDS-PAGE Analysis	57
4.5	Detection of Leptospira-Specific IgM and IgG in ELISA	58
4.5.1	Distribution of Leptospira-Specific Antibodies in Human Serum Sample using Single Serum Dilution (1:400)	65
4.6	Sensitivity and Specificity of rLipL32 Based ELISA Assay	69
4.7	Measuring the Level of the Regulatory Cytokine, IL-10 for Determination of Disease Severity	70
CHAPTER 5: DISCUSSION		73
5.1	Generation of Synthetic <i>lip32</i> Gene	73
5.2	Screening of Transformation for <i>lip32</i> Inserts	75
5.3	Expression Level of <i>lip32</i> Gene in <i>E.coli</i> and Solubility of the rLipL32 Protein	76
5.4	Production of Purified Synthetic rLipL32 Protein	77

5.5	Detection of Leptospira-Specific IgM and IgG in ELISA	78
5.6	Sensitivity and Specificity of rLipL32 Based ELISA Assay	81
5.7	Measuring the Levels of the Regulatory Cytokine, IL-10 for Determination of Disease Severity	82
CHAPTER 6: CONCLUSION		84
REFERENCES		87
APPENDIX		108
	Appendix A	108
	Appendix B	110
	Appendix C	115
	Appendix D	116
	Appendix E	117
	Appendix F	118
	Appendix G	119
	Appendix H	120
	Appendix I	121
	Appendix J	122
	Appendix K	123
	Appendix L	127



UMS
UNIVERSITI MALAYSIA SABAH

LIST OF TABLES

	Page
Table 2.1: Reservoirs of Different <i>Leptospira</i> Serovar	7
Table 2.2: Lists of Known <i>Leptospira</i> Species	8
Table 2.3: Features of The Genomes of Pathogenic and Saprophytic <i>Leptospira</i> Species	9
Table 2.4: Recent Incidence of Leptospirosis in Malaysia	12
Table 2.5: Details of Treatments in Leptospirosis Patients	15
Table 2.6: Laboratory Diagnostic Methods for Leptospirosis	30
Table 3.1: Primer used in Colony PCR Reaction	35
Table 3.2: Components for Colony PCR	35
Table 3.3: Components for Restriction Enzyme Digestions	37
Table 3.4: Concentration and Volume of Components for Preparation of 10 % Resolution Gels (a) and 1.5 % Stacking Gels (b)	39
Table 3.5: Sample Preparation for SDS-PAGE Analysis	40
Table 4.1: Detections of <i>Leptospira</i> -Specific IgM and IgG in MAT Positive and Negative Human Serum Samples. Unknown Samples were used to Standardize the ELISA. RCPA Samples were used for Quality Assurance	65
Table 4.2: Sensitivity and Specificity of IgM and IgG ELISA	69
Table 4.3: Detections of IL-10 in MAT Positive Serum Sample	71

LIST OF FIGURES

	Page
Figure 2.1: Shadowed electron photomicrograph of <i>Leptospira</i> species. This figure shows the morphology of unique hook or question mark-shaped ends of <i>Leptospira</i> species	7
Figure 2.2: Original observation of spirochete in kidney tissue by Stimson in 1907	10
Figure 2.3: Figures showing the structure of LipL32 in the form of a (a) crystal structure; and (b) topology diagram	18
Figure 2.4: The schematic diagram representative of human IgG domain	20
Figure 2.5: The pentamer shape of IgM. Each subunits are linked with disulphide bonds and J chain	21
Figure 3.1: The positive transformants were sub-cultured onto new LB plates (ampicillin 100µg/ml) in grid	34
Figure 3.2: Flow chart for isolation, solubilization and purification of rLipL32 protein	43
Figure 4.1: The schematic diagram of the codon optimized <i>lipL32</i> gene construct in pET22b vector. The <i>lipL32</i> gene was inserted into the ORF of pET22b vector using BamHI and EcoRI	48
Figure 4.2: Nucleotide sequence of codon optimized <i>lipL32</i> gene with 828 bases in size. The font in blue indicates the BamHI restriction sites. The font in green indicates the EcoRI restriction site. The font in black bold and highlighted in grey indicates the extra 'C' base added to the optimized sequence	49
Figure 4.3: Agarose gel electrophoresis of colony PCR analysis <i>E.coli</i> BL21 (DE3). Lane M: 1 kb DNA ladder (Promega).	50
Figure 4.4: Agarose gel electrophoresis of restriction enzyme digestion of the PCR products using EcoRI and BamHI restriction enzymes from positive transformants. Lane M: 1 kb DNA ladder (Promega)	52

Figure 4.5	SDS-PAGE gel from <i>E.coli</i> BL21 (DE3) expressing rLipL32 protein under various incubation times (inclusion bodies protein). Lane M: Low range protein ladder (Nacalai).	53
Figure 4.6	SDS-PAGE gel from <i>E.coli</i> BL21 (DE3) expressing rLipL32 protein under various incubation times (soluble protein). Lane M: Low range protein ladder (Nacalai)	54
Figure 4.7	Chromatogram showing the affinity chromatography of rLipL32 protein with single wavelength detection (UV 280 nm). The peak observed on the chromatogram, as indicated by arrow is the purified rLipL32 protein	56
Figure 4.8	SDS PAGE analysis of expression rLipL32 protein and purification of rLipL32 protein. The proteins were separated on 10 % SDS PAGE gel and stained with Commasie blue. Lane M: Low range protein ladder (Nacalai)	57
Figure 4.9	Different level of Leptospira-specific IgM detected in MAT positive serum samples. Each well was coated with 0.25 µg of purified rLipL32 antigen. Serum samples were serially diluted starting at 1:100 and increased two-fold in successive dilutions up to 1:3200.	59
Figure 4.10	Different level of Leptospira-specific IgG detected in MAT positive serum samples. Each well was coated with 0.25 µg of purified rLipL32 antigen. Serum samples were serially diluted starting at 1:100 and increased two-fold in successive dilutions up to 1:3200	60
Figure 4.11	Different level of Leptospira-specific IgM detected in MAT negative serum samples. Each well was coated with 0.25 µg of purified rLipL32 antigen. Serum samples were serially diluted starting at 1:100 and increased two-fold in successive dilutions up to 1:3200	61
Figure 4.12	Different level of Leptospira-specific IgG detected in MAT negative serum samples. Each well was coated with 0.25 µg of purified rLipL32 antigen. Serum samples were serially diluted starting at 1:100 and increased two-fold in successive dilutions up to 1:3200	62
Figure 4.13	Different levels of Leptospira-specific IgM detected in RCPA samples. Each well was coated with 0.25 µg of purified rLipL32 antigen. Serum samples were serially diluted starting at 1:100 and increased two-fold in successive dilutions up to 1:3200	63

Figure 4.14	Different levels of Leptospira-specific IgG detected in RCPA samples. Each well was coated with 0.25 µg of purified rLipL32 antigen. Serum samples were serially diluted starting at 1:100 and increased two-fold in successive dilutions up to 1:3200	63
Figure 4.15	The survey report from RCPA for synthetic rLipL32 ELISA shows the assay scored 71 %	64
Figure 4.16	Distributions of Leptospira-specific IgM in MAT positive serum samples using single serum dilution at 1:400	66
Figure 4.17	Distributions of Leptospira-specific IgG in MAT positive serum samples using single serum dilution at 1:400	67
Figure 4.18	Distributions of Leptospira-specific IgM in MAT negative serum samples using single serum dilution at 1:400	68
Figure 4.19	Distributions of Leptospira-specific IgG in MAT negative serum samples using single serum dilution at 1:400	69
Figure 4.20	IL-10 levels in MAT positive serum samples	72




LIST OF ABBREVIATIONS

µg	-	Microgram
µL	-	Microliter
1 st	-	First
2 nd	-	Second
Bp	-	Base pair
g	-	Gram
g	-	Gravity
hr	-	Hour
hrs	-	Hours
kDA	-	Kilo Dalton
kg	-	Kilogram
L	-	Litre
Mb	-	Mega base
mg	-	Milligram
mL	-	Millilitre
OD	-	Optical density
RCPA	-	Royal College of Pathologists of Australasia
RE	-	Restriction Enzyme
rLipL32	-	Recombinant LipL32
rpm	-	Rotation per minute
UV	-	Ultra violet

LIST OF SYMBOLS

- % - Percentage
°C - Degree Celsius



UMS
UNIVERSITI MALAYSIA SABAH

LIST OF APPENDICES

	Page
Appendix A: Preparation of Solutions for Electrophoresis Purposes	108
Appendix B: Preparation of Media and Solutions	110
Appendix C: Circle Maps and Multiple Cloning Sites (MSC) of Vector Used	115
Appendix D: The Native LipL32 Amino Acid Sequence (NCBI Accession number; ACZ73827.1)	116
Appendix E: Native Sequence of <i>lip32</i> Gene and Optimized Sequence and Their Deduced Amino Acid	117
Appendix F: Codon Usage of Native Sequence and Codon Optimized Sequence	118
Appendix G: Standardization of ELISA (Using 11 Serum Samples from Tuaran Hospital)	119
Appendix H: Reference Number for Tested Serum Samples	120
Appendix I: Detection of Leptospira-Specific IgM and IgG in ELISA (MAT Positive Samples)	121
Appendix J: Detection of Leptospira-Specific IgM and IgG in ELISA (MAT Negative Samples)	122
Appendix K: The Absorbance Values of the Tested Serum Samples at 1:400 Dilution	123
Appendix L: Standard Graphs for IL-10 ELISA	127

CHAPTER 1

INTRODUCTION

1.1 Preface

Leptospirosis, caused by infection of pathogenic *Leptospira interrogans* (*L. interrogans*) is a zoonotic disease affecting both human and animals. Based on data by the World Health Organization's Leptospirosis Burden Epidemiology References (LERG), there is an estimated 873,000 cases of human Leptospirosis reported annually with 48,000 fatalities (Bandara *et al.*, 2014). Countries with the highest reported incidence are located in the Caribbean, Latin America, Indian subcontinents, Southeast Asia, Oceania and Eastern Europe (Pappas *et al.*, 2008; Shafei *et al.*, 2012).

In recent years, outbreaks of human Leptospirosis has been observed to be related to recreational activities and consequently emerged as a strong risk-factor for Leptospirosis transmission (Bandara *et al.*, 2014). Moreover, human Leptospirosis cases among international travellers have increased in the past twenty years, thus causing major public health concern worldwide (Ricaldi and Vinetz, 2006).

Up to the present day, diagnosis of Leptospirosis remains a challenge. Though microscopic agglutination test (MAT) assay is the gold standard for diagnosis of *Leptospira* infection, this assay is not effective in detection at the early phase of the disease. Therefore, researchers have attempted to develop different enzyme-linked immunosorbent assays (ELISAs) for early detection of *Leptospira*

infections using recombinant *Leptospira* outer membrane proteins (OMP) as antigens (Dey *et al.*, 2004; Tomich *et al.*, 2007; Chen *et al.*, 2013; Alizadeh *et al.*, 2014).

Most of these assays focused on detection of the LipL32 protein, which is found abundantly in *Leptospira* total protein profile and one of the most important OMPs expressed during human infection of Leptospirosis in addition to being highly conserved in pathogenic *Leptospira* species (Khodaverdi *et al.*, 2013; Haake *et al.*, 2000). *Leptospira* OMP was suggested to have a role in the mechanism of evasion of the immune response as well as the persistence in the host (Patricia *et al.*, 2014). LipL32 has been identified as an extracellular matrix (ECM) binding protein which specifically binds to fibronectin, collagen I and laminin (Patricia *et al.*, 2014). A guinea pig model of Leptospirosis showed that LipL32 protein is expressed during leptospiral infection (Hoke *et al.*, 2008) and also shown to be capable of inducing tubulointerstitial nephritis in mouse proximal tubule cells (Yang *et al.*, 2002; Haake *et al.*, 2000).

Various ELISAs using rLipL32 have been developed for detection of Leptospirosis in humans (Flannery *et al.*, 2001; Chen *et al.*, 2013), canines (Dey *et al.*, 2004), bovines (Tomich *et al.*, 2007) and swine (Hartleben *et al.*, 2013). In these studies, the *lip32* gene was isolated by using a specific set of primers, then the PCR-amplified gene was cloned into an expression vector and transformed into a bacterial host for production of the rLipL32. The purified protein then served as antigen in each ELISA developed. Varying levels of performance were also noted among these studies. The rLipL32 ELISA which was developed by Flannery *et al.* (2001), has the sensitivity and specificity of 56 % and 95 % respectively. On the other hand, Chen *et al.* (2013) has demonstrated 65 % sensitivity. The sensitivity and specificity in bovine rLipL32 ELISA (Tomich *et al.*, 2007) was 99.3 % and 86.33 % respectively. Meanwhile, the rLipL32 ELISA in swine (Hartleben *et al.*, 2013) has the sensitivity of 100 % and 85.1 % of specificity. On the contrary, the rLipL32 ELISA in the current study was developed by using the codon optimization method.

Limited study use codon optimized gene for the diagnosis of human Leptospirosis. Essentially, the current study shows the performance of the rLipL32 ELISA developed from the codon optimized gene.

Organ damages have been observed in severe Leptospirosis (Weil's disease) which involves immune response of the host towards *Leptospira* infection. Several mediators have been suggested to play a role in Leptospirosis pathogenesis, including tumour necrosis factor alpha (TNF- α), interleukin-10 (IL-10), interleukin-8 (IL-8), interleukin-6 (IL-6), and interleukin-1 beta (IL-1 β). Thus, assessing the levels of these cytokines in patients would provide an insight to the degree of severity of the Leptospirosis (Kyriakidis *et al.*, 2011; Reis *et al.*, 2013; Chirathaworn and Kongpan, 2013).

In this study, the synthetic gene encoding LipL32 protein was designed and followed by expression in *Escherichia coli*. The expressed protein was purified and subsequently used as antigens in ELISA for detection of *Leptospira*-specific antibodies in human serum samples. IL-10, a regulatory cytokine was measured in positive serum samples.

1.2 Objectives

The objectives of this research can be divided into three parts:

1. To express and purify the synthetic recombinant LipL32 protein in *E.coli*.
2. To determine the presence of *Leptospira*-specific antibodies in human serum samples using synthetic recombinant LipL32 antigen in ELISA.
3. To measure the level of regulatory cytokine, IL-10 for the determination of disease severity.

1.3 Research Approach

There are three approaches towards achieving the objectives. The first approach is to design a synthetic gene encoding the LipL32 protein. The LipL32 amino acid sequence for protein (GenBank accession number ACZ73827.1) was used for generation of the synthetic gene. The synthetic gene was codon-optimized for expression in *E.coli* BL21 (DE3). The DNA sequence generated after reverse translation of the optimized codons. The optimized codon or synthetic gene was custom cloned into pET22b vector and transformed into *E.coli* BL21 (DE3) for protein expression and protein production.

The second approach uses the immobilized metal affinity chromatography (IMAC) to purify the expressed rLipL32 protein. HisTrap FF Crude column from GE Healthcare is used to purify the protein through AKTA Pure System. The purified rLipL32 later used as antigen in ELISA for detection of Leptospira-specific antibodies in human serum samples.

The third approach uses Human IL-10 ELISA kit from BD, Bioscience to assess the level of IL-10 presence in MAT positive serum samples. The level of the IL-10 in the serum samples were compared to the previous studies for the determination of the degree of disease severity.

CHAPTER 2

LITERATURE REVIEW

2.1 Overview of Leptospirosis

Leptospirosis is a zoonotic disease occurs worldwide. It is endemic in tropical and subtropical countries in South-East Asia (Shafei *et al.*, 2012). An increase in incidents has been seen in recent years due to flooding and outdoor recreational activities (Lim, 2011). Accurate clinical diagnosis can be difficult without laboratory confirmation and the disease burden is generally under-reported. World Health Organization (WHO) has formed Leptospirosis Burden Epidemiology Reference Group (LERG) to establish correct estimations of the disease burden for better adequate intervention, control and prevention (WHO, 2010). The incubation period for Leptospirosis is 2 days to 4 weeks and the illness begins abruptly with fever.

Leptospirosis may occur in two phases. In the first phase, the symptoms which can be observed are fever, chills, severe headache, nausea, vomiting, myalgia and diarrhoea. Many of these symptoms can be mistaken for other diseases. The patient usually recovers for a time but become ill again. The second phase is called Weil's disease and is more severe and the symptoms include sepsis with multiple organ dysfunction, jaundice and haemorrhage which turn to circulatory shock and eventually death (Wagenaar *et al.*, 2009). The illness lasts from few days to 3 weeks and without treatment, recovery may take several months (Musso and Scola, 2013).

2.2 *Leptospira*, The Organism

Leptospire are spirochetes, which are thin, highly motile with an approximate size of 0.1µm in diameter and 6-20 µm in length with a distinctive hook or question-mark shape (Adler and Moctezuma, 2010) (Figure 2.1). The genus *Leptospira* can be divided into pathogenic and saprophytic strains, which belongs to the family Leptospiraceae and order Spirochaetales. Currently, there are 23 species, 25 serogroups and 250 serovars of pathogenic leptospire have been described and usually associated with natural host (Musso and Scola, 2013; Levett, 2015) (Table 2.1). Table 2.2 shows 23 *Leptospira* species that have been identified so far (Levett, 2015). The serovar classification of *Leptospira* is based on the expression of the surface-exposed epitopes in a mosaic of the lipopolysaccharide (LPS) antigens and the specificity of the epitopes depends on their sugar composition and orientation (Adler and Moctezuma, 2010).

Leptospire are slow-growing obligate aerobes with an optimal growth temperature of 28°C-30°C (Faine *et al.*, 1999). Leptospire can grow in simple media enriched with vitamin B1 and B2, ammonium salts and long-chain of fatty acids (Faine *et al.*, 1999). The most widely used media to culture leptospire is the Ellinghausen-McCulloch-Johnson-Harris (EMJH) medium which contains oleic acid, bovine serum albumin (BSA), and polysorbate (Tween) (Adler and Moctezuma, 2010).

The genome size of *Leptospira* is approximately 3.9-4.6 Mb (megabase) depending on the species. Six genome sequences of *Leptospira* have been published including two isolates of *L. interrogans* (serovar Lai and Copenhageni), two isolates of *L. borgpetersenii* (serovar Hardjo) and two isolate of *L. biflexa* (serovar Patoc) (Bulach *et al.*, 2006; Picardeau *et al.*, 2008; Adler and Moctezuma, 2010). The features of these genomes are summarized in Table 2.3.